Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Adaptimmune Therapeutics Plc
ADAPCurrent price
0.26 USD
+0.011 USD (+4.50%)
Last closed
0.26 USD
Company
www.adaptimmune.com
ISIN
US00653A1079
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
61 272 660 USD
Yield for 12 month
-75.71 %
1Y
3Y
5Y
10Y
15Y
ADAP
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Address: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1.71 USDP/E ratio
–Dividend Yield
–Current Year
+178 032 000 USD
Last Year
+60 281 000 USD
Current Quarter
+3 222 000 USD
Last Quarter
+40 901 000 USD
Current Year
+177 962 000 USD
Last Year
+50 423 941 USD
Current Quarter
+3 222 000 USD
Last Quarter
+40 901 000 USD
Key Figures ADAP
1 year
3 years
5 years
10 years
EBITDA
-41 184 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-12.39 %
PEG Ratio
0.11
Return On Equity TTM
-275.74 %
Wall Street Target Price
1.71 USD
Revenue TTM
178 032 000 USD
Book Value
0.046 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
1 294.80 %
Dividend Yield
–
Gross Profit TTM
28 902 000 USD
Earnings per share
-0.30 USD
Diluted Eps TTM
-0.30 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-39.78 %
Dividend Analytics ADAP
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History ADAP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation ADAP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.64
Price Sales TTM
0.34
Enterprise Value EBITDA
-1.71
Price Book MRQ
5.17
Financials ADAP
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ADAP
For 52 weeks
0.20 USD
1.48 USD
50 Day MA
0.41 USD
Shares Short Prior Month
5 642 793
200 Day MA
0.76 USD
Short Ratio
2.26
Shares Short
5 454 233
Short Percent
3.17 %
BeatStart